Cargando…

Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis

BACKGROUND: This study uses the tandem mass tag (TMT)-labeled quantitative proteomic analysis to identify potential therapeutic protein targets of a Chinese prescription called Tang-Yi-Ping (TYP) for the treatment of impaired glucose tolerance (IGT) in rats. METHODS: A total of 31 specific-pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Bu, Shuai, Zhou, Honglei, Bi, Siling, Xu, Yunsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576661/
https://www.ncbi.nlm.nih.gov/pubmed/34790738
http://dx.doi.org/10.21037/atm-21-4257
_version_ 1784595921175052288
author Li, Jie
Bu, Shuai
Zhou, Honglei
Bi, Siling
Xu, Yunsheng
author_facet Li, Jie
Bu, Shuai
Zhou, Honglei
Bi, Siling
Xu, Yunsheng
author_sort Li, Jie
collection PubMed
description BACKGROUND: This study uses the tandem mass tag (TMT)-labeled quantitative proteomic analysis to identify potential therapeutic protein targets of a Chinese prescription called Tang-Yi-Ping (TYP) for the treatment of impaired glucose tolerance (IGT) in rats. METHODS: A total of 31 specific-pathogen free (SPF) male Wistar rats were used in our study. Ten were randomly selected as a control group, while 21 received a high-sugar and high-fat diet combined with an intraperitoneal injection of streptozotocin to establish IGT subjects. After eliminating 2 rats without successful modeling, 19 were randomly divided into a TYP group (n=9) and IGT model group (n=10). The TYP group was given a TYP decoction of 6.36 mg/kg−1/d−1. After 8 weeks of intervention, blood glucose-related indicators were measured, and cell morphology was observed by hematoxylin and eosin (HE) staining. TMT-labeled proteomic analysis was applied to detect the differentially expressed proteins (DEPs) in the pancreases of the three groups. The intersection of the DEPs in both the TYP group and IGT model group underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses to identify the related biological functions and signal transduction pathways. Finally, western blot (WB) was used to verify the TMT proteomics results. RESULTS: TYP can effectively reduce blood glucose and improve islet morphology in IGT rats. We identified a total of 16 potential therapeutic protein targets of TYP, 4 of which were upregulated, while 12 were downregulated, including Rbp4, Fam3b, Flot2, etc. [fold change (FC) >1.1, P<0.05]. The significant signal transduction pathways included arginine and proline metabolism, glyceride metabolism, glycerophospholipid metabolism, mTOR, Wnt, and insulin signaling pathways. CONCLUSIONS: For anti-IGT therapy, we found TYP regulates 16 protein targets, multiple biological functions, and multiple signal transduction pathways. This study thus makes a significant contribution to identifying new potential therapeutic targets for treating IGT.
format Online
Article
Text
id pubmed-8576661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85766612021-11-16 Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis Li, Jie Bu, Shuai Zhou, Honglei Bi, Siling Xu, Yunsheng Ann Transl Med Original Article BACKGROUND: This study uses the tandem mass tag (TMT)-labeled quantitative proteomic analysis to identify potential therapeutic protein targets of a Chinese prescription called Tang-Yi-Ping (TYP) for the treatment of impaired glucose tolerance (IGT) in rats. METHODS: A total of 31 specific-pathogen free (SPF) male Wistar rats were used in our study. Ten were randomly selected as a control group, while 21 received a high-sugar and high-fat diet combined with an intraperitoneal injection of streptozotocin to establish IGT subjects. After eliminating 2 rats without successful modeling, 19 were randomly divided into a TYP group (n=9) and IGT model group (n=10). The TYP group was given a TYP decoction of 6.36 mg/kg−1/d−1. After 8 weeks of intervention, blood glucose-related indicators were measured, and cell morphology was observed by hematoxylin and eosin (HE) staining. TMT-labeled proteomic analysis was applied to detect the differentially expressed proteins (DEPs) in the pancreases of the three groups. The intersection of the DEPs in both the TYP group and IGT model group underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses to identify the related biological functions and signal transduction pathways. Finally, western blot (WB) was used to verify the TMT proteomics results. RESULTS: TYP can effectively reduce blood glucose and improve islet morphology in IGT rats. We identified a total of 16 potential therapeutic protein targets of TYP, 4 of which were upregulated, while 12 were downregulated, including Rbp4, Fam3b, Flot2, etc. [fold change (FC) >1.1, P<0.05]. The significant signal transduction pathways included arginine and proline metabolism, glyceride metabolism, glycerophospholipid metabolism, mTOR, Wnt, and insulin signaling pathways. CONCLUSIONS: For anti-IGT therapy, we found TYP regulates 16 protein targets, multiple biological functions, and multiple signal transduction pathways. This study thus makes a significant contribution to identifying new potential therapeutic targets for treating IGT. AME Publishing Company 2021-10 /pmc/articles/PMC8576661/ /pubmed/34790738 http://dx.doi.org/10.21037/atm-21-4257 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, Jie
Bu, Shuai
Zhou, Honglei
Bi, Siling
Xu, Yunsheng
Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
title Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
title_full Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
title_fullStr Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
title_full_unstemmed Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
title_short Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
title_sort identifying potential therapeutic targets of tang-yi-ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576661/
https://www.ncbi.nlm.nih.gov/pubmed/34790738
http://dx.doi.org/10.21037/atm-21-4257
work_keys_str_mv AT lijie identifyingpotentialtherapeutictargetsoftangyipingforthetreatmentofimpairedglucosetoleranceatandemmasstaglabeledquantitativeproteomicanalysis
AT bushuai identifyingpotentialtherapeutictargetsoftangyipingforthetreatmentofimpairedglucosetoleranceatandemmasstaglabeledquantitativeproteomicanalysis
AT zhouhonglei identifyingpotentialtherapeutictargetsoftangyipingforthetreatmentofimpairedglucosetoleranceatandemmasstaglabeledquantitativeproteomicanalysis
AT bisiling identifyingpotentialtherapeutictargetsoftangyipingforthetreatmentofimpairedglucosetoleranceatandemmasstaglabeledquantitativeproteomicanalysis
AT xuyunsheng identifyingpotentialtherapeutictargetsoftangyipingforthetreatmentofimpairedglucosetoleranceatandemmasstaglabeledquantitativeproteomicanalysis